Genetic Testing Has Undergone Revolutionary Changes Since 2010
Yes, genetic testing has fundamentally transformed since 2010, evolving from targeted single-gene tests and chromosomal microarrays to comprehensive genome and exome sequencing that is now widely accessible in clinical practice, with approximately 75,000 genetic tests currently on the market and 10 new tests entering daily. 1, 2
Major Technological Shifts
The landscape has shifted dramatically in both scope and scale:
Before 2010: Clinical genetics relied primarily on:
- G-banded karyotyping for chromosomal abnormalities
- Single-gene sequencing for specific suspected conditions
- Chromosomal microarray (CGH and SNP arrays) as the highest-resolution genome-wide test 1
After 2010: The field rapidly adopted:
- Clinical genome and exome sequencing (CGES) became widely available for diagnostics starting around 2010-2012 1
- Multigene panels that can sequence dozens to hundreds of genes simultaneously at costs comparable to previous single-gene tests 3
- Next-generation sequencing platforms that replaced earlier methods 4
- Testing volume increased dramatically, with one facility reporting rapid expansion specifically after 2010 4
Expansion in Test Availability and Spending
The market has exploded exponentially:
- By 2014-2017, approximately 75,000 genetic tests were available commercially 2
- Ten new tests enter the market daily 2
- Prenatal testing accounts for the highest spending, followed by hereditary cancer testing 2
- Testing is no longer restricted to highest-risk patients but is moving toward testing all cancer patients and even population-wide screening 5
Shift in Clinical Practice Paradigms
The practice model has fundamentally changed from restrictive, criteria-based testing to broader access:
- Traditional risk criteria (family history, age) are neither sensitive nor specific enough to identify all at-risk individuals 5
- The field is transitioning from testing only high-risk patients to universal testing for all cancer patients 5
- Population screening studies (Healthy Nevada, MyCode) have demonstrated a prevalence of 1 in 70 individuals carrying pathogenic variants for CDC Tier 1 conditions in the general population 5
Increased Complexity and New Challenges
The comprehensiveness of testing has created new interpretive challenges:
- Variants of uncertain significance (VUS) are identified in large numbers with CGES 1
- Secondary findings (incidental findings unrelated to the primary indication) occur in 0.5-3.5% of individuals undergoing CGES 1
- Laboratory interpretation of variant significance can vary between facilities 3
- The evidence base for clinical utility has not kept pace with technological advancement, necessitating new frameworks like Clinical Practice Advisory Documents (CPADs) to bridge the gap until definitive guidelines can be developed 3
Service Delivery Model Transformation
New delivery mechanisms have emerged to handle the scale of testing:
- Mainstreaming genetic testing into oncology clinics rather than restricting to genetics specialists 5
- Use of videos, testing kiosks, chatbots, and genetic counseling assistants to facilitate large-scale testing 5
- These alternative delivery models show good patient uptake and satisfaction 5
Common Pitfalls to Avoid
When ordering genetic testing in the current era:
- Don't rely solely on traditional family history criteria to determine who should be tested—they miss many at-risk individuals 5
- Anticipate VUS results and counsel patients preemptively about uncertainty 1
- Prepare for secondary findings that may require additional management 1
- Verify laboratory quality as interpretation standards vary between facilities 3
The transformation since 2010 represents a shift from targeted, hypothesis-driven testing to comprehensive genomic analysis that is increasingly accessible, affordable, and moving toward population-level implementation 1, 5, 2.